ライフサイエンスコーパス: basal cell

1 inhibition allowed rapid expansion of airway basal cells.

2 H3N2 was also detected in rare goblet and basal cells.

3 d in reserve, and mitotically active globose basal cells.

4 populations due to the presence of germinal basal cells.

5 -mediated expression of RNase 7 in remaining basal cells.

6 cells and a spatial gradient of apoptosis of basal cells.

7 euroendocrine carcinoma and primary prostate basal cells.

8 pithelia derived from normal human bronchial basal cells.

9 located at the interface between luminal and basal cells.

10 i-ciliated and a layer of Keratin-5-positive basal cells.

11 l cells are molecularly distinct from Krt15- basal cells.

12 of several epithelia, but suppressed in p63+ basal cells.

13 cells, whereas basal cells divided only into basal cells.

14 trachea during epithelial regeneration from basal cells after injury.

15 M(+) luminal progenitors, which express both basal cell and luminal cell-enriched genes.

16 intercellular spaces (confirmed by CLE), and basal cell and papillary hyperplasia developed without s

17 cyte-predominant esophageal inflammation and basal cell and papillary hyperplasia without loss of sur

18 Also evaluated were changes in epithelial basal cell and papillary hyperplasia, surface erosions,

19 Basal cell and squamous cell carcinomas of the skin are

20 Bioinformatic analysis of the basal cell and two human small cell gene signatures iden

21 ferentiation of keratin 5-positive (Krt5(+)) basal cells and ectopic expression of squamous-like diff

22 ers differentiated from primary human airway basal cells and examined by advanced imaging.

23 Os possess upper airway-like epithelium with basal cells and immature ciliated cells surrounded by sm

24 asal stem cells, frequently dividing globose basal cells and quiescent horizontal basal cells (HBCs).

25 Ezh2 regulates the phenotypic switch between basal cells and secretory cells.

26 18.5, intermediate cells differentiated into basal cells and superficial cells.

27 en activating reserve stem cells (horizontal basal cells) and Neurogenin1 (+) immediate neuronal prec

28 an abundant product of normal mammary gland basal cells, and that alpha3(V) ablation in a mouse mamm

29 Using RNA-seq, we show that basal cells are extraordinarily transcriptionally dynami

30 riptional profiling demonstrated that Krt15+ basal cells are molecularly distinct from Krt15- basal c

31 Basal cells are multipotent airway progenitors that gene

32 In this study, we report that basal cells are the principal cell type producing RNase

33 led cells include both proliferative globose basal cells as well as immature OSNs exhibiting the hall

34 T-mTORC1-NFkappaB-MMP9 pathway activation in basal cells, as well as systemic isotonicity, prevents m

35 To identify signals controlling basal cell behavior we screened factors that alter their

36 rom the neural crest, with the secretory and basal cells being of urogenital sinus origin.

37 luminal cells and an excessive expansion of basal cells, both in vivo and in vitro The inability to

38 sing cells with a decreased number of CK5(+) basal cells but an increase of CK8(+) luminal tumorigeni

39 teins not previously identified in olfactory basal cells but known to be essential for self-renewal i

40 The selective induction of RNase 7 in basal cells by cigarette smoke was demonstrated using co

41 ssay, our group previously demonstrated that basal cells can serve as efficient targets for transform

42 Basal cell cancers (BCCs) are characterized by upregulat

43 Strikingly, basal cell carcinogenesis only occurs when Atp1b1a funct

44 3%]), cutaneous SCC (11 of 21 tumors [52%]), basal cell carcinoma (3 of 4 tumors [75%]), and ACC (5 o

45 s in human skin biopsy samples diagnosed for basal cell carcinoma (BCC) and compared with healthy ski

46 Patients with basal cell carcinoma (BCC) and cutaneous squamous cell c

47 We report a case of local recurrence of basal cell carcinoma (BCC) and ocular complications foll

48 Whether susceptible people develop both basal cell carcinoma (BCC) and squamous cell carcinoma (

49 mance of this methodology on differentiating basal cell carcinoma (BCC) and squamous cell carcinoma (

50 Keratinocyte cancers (KCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (

51 f nonmelanoma skin cancer (NMSC), defined as basal cell carcinoma (BCC) and squamous cell carcinoma (

52 tance: Keratinocyte cancers (KCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (

53 ng DSCMs before and after training to detect basal cell carcinoma (BCC) and squamous cell carcinoma (

54 in cancers using a population-based study of basal cell carcinoma (BCC) and squamous cell carcinomas

55 Basal cell carcinoma (BCC) are common in this age group

56 expression and its clinical significance in basal cell carcinoma (BCC) are unknown to date.

57 The effect of UVR on human basal cell carcinoma (BCC) epidemiology is complex-the i

58 Basal cell carcinoma (BCC) incidence is increasing, part

59 Basal cell carcinoma (BCC) is characterized by frequent

60 Basal cell carcinoma (BCC) is the most common cancer wor

61 Basal cell carcinoma (BCC) is the most common type of sk

62 Basal cell carcinoma (BCC) of the skin is the most commo

63 s between cigarette smoking and incidence of basal cell carcinoma (BCC) or squamous cell carcinoma (S

64 the cancer-associated microRNA-21 (miR21) in basal cell carcinoma (BCC) skin tumors.

65 melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC)) in prospective studies simul

66 itor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and shows promise in clinica

67 a new type of targeted therapy for advanced basal cell carcinoma (BCC), and their long-term effects,

68 ts who develop recurrent or locally advanced basal cell carcinoma (BCC), and will inevitably be integ

69 he INTU gene is aberrantly elevated in human basal cell carcinoma (BCC), coinciding with increased pr

70 cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), in part as a result of immun

71 risk estimates to evaluate the risks of SCC, basal cell carcinoma (BCC), keratinocyte cancers (KCs) o

72 ry outcomes were time to first appearance of basal cell carcinoma (BCC), squamous cell carcinoma (SCC

73 Importance: Rates of skin cancer, including basal cell carcinoma (BCC), the most common cancer, have

74 Basal cell carcinoma (BCC), the most common human cancer

75 tion exposure is the primary risk factor for basal cell carcinoma (BCC), the most common human malign

76 uence variants that confer risk of cutaneous basal cell carcinoma (BCC), we conduct a genome-wide ass

77 particularly evident in medulloblastoma and basal cell carcinoma (BCC), where inhibitors targeting t

78 moothened (SMO) inhibitor-treated metastatic basal cell carcinoma (BCC).

79 umption is associated with risk of cutaneous basal cell carcinoma (BCC).

80 verall), nonmelanoma skin cancer (NMSC), and basal cell carcinoma (BCC).

81 us cell carcinoma, and a superficial type of basal cell carcinoma (BCC).

82 ecule and are indicated for locally advanced basal cell carcinoma (laBCC) and metastatic basal cell c

83 basal cell carcinoma (laBCC) and metastatic basal cell carcinoma (mBCC).

84 as also associated with an increased risk of basal cell carcinoma (OR, 1.19 [95% CI, 1.14-1.25], 9% f

85 The recurrence rate of periocular nodular basal cell carcinoma (PNBCC) following treatment with im

86 13), 499 patients (468 with locally advanced basal cell carcinoma and 31 with metastatic basal cell c

87 n clinical benefit in patients with advanced basal cell carcinoma and is approved for treatment of pa

88 ns in Smoothened (SMO) have been reported in basal cell carcinoma and medulloblastoma, but are largel

89 included intradermal nevus misclassified as basal cell carcinoma and nonmelanocytic lesions (eg, seb

90 Hedgehog signaling, where Ptch1 loss causes basal cell carcinoma and Ptch1;Ptch2 loss disrupts skin

91 ere noted among the 42 with locally advanced basal cell carcinoma and two (15%, 2-45) among the 13 wi

92 ared with surgery for superficial or nodular basal cell carcinoma at low-risk sites in our noninferio

93 c modality from which patients with advanced basal cell carcinoma can benefit substantially.

94 oved for treatment of patients with advanced basal cell carcinoma for whom surgery is inappropriate.

95 -71.0) of 453 patients with locally advanced basal cell carcinoma had an overall response (153 comple

96 %; 20.7-57.7) of 29 patients with metastatic basal cell carcinoma had an overall response (two comple

97 Patients with locally advanced basal cell carcinoma had to have been deemed ineligible

98 Patients with advanced basal cell carcinoma have limited treatment options.

99 f melanoma; overall and by stage and risk of basal cell carcinoma in multivariable logistic regressio

100 Basal cell carcinoma in the very elderly were more commo

101 en's Hospital Oakland Research Institute and Basal Cell Carcinoma Nevus Syndrome Life Support Network

102 Eligible patients had locally advanced basal cell carcinoma not amenable to curative surgery or

103 th histologically confirmed locally advanced basal cell carcinoma or metastatic basal cell carcinoma

104 ed a diagnosis of and were being treated for basal cell carcinoma or squamous cell carcinoma (cases)

105 Multiple hereditary infundibulocystic basal cell carcinoma syndrome (MHIBCC) is a rare genoder

106 key RCM diagnostic criteria for melanoma and basal cell carcinoma that are reproducibly recognized am

107 advanced basal cell carcinoma or metastatic basal cell carcinoma were recruited from regional referr

108 Patients with histologically confirmed basal cell carcinoma who received at least one dose of s

109 basal cell carcinoma and 31 with metastatic basal cell carcinoma) had received study drug and had th

110 icial basal cell carcinoma, 6 weeks; nodular basal cell carcinoma, 12 weeks) or excisional surgery (4

111 o imiquimod 5% cream once daily (superficial basal cell carcinoma, 6 weeks; nodular basal cell carcin

112 treatment option for patients with advanced basal cell carcinoma, a population that is difficult to

113 n increased risk of squamous cell carcinoma, basal cell carcinoma, and melanoma.

114 Basal cell carcinoma, solar keratosis, and colorectal ca

115 immunosuppressed = 8.9 years), 135 (27%) had basal cell carcinoma, squamous cell carcinoma or Bowen's

116 organ transplant population at high risk for basal cell carcinoma, therapeutic options for locally ad

117 t (1 malignancy) also developed a periocular basal cell carcinoma.

118 ncluding medulloblastoma, ameloblastoma, and basal cell carcinoma.

119 curative surgery or radiation or metastatic basal cell carcinoma.

120 therapies for Hh-dependent cancers, such as basal cell carcinoma.

121 clinical practice for patients with advanced basal cell carcinoma.

122 um antibodies and cSCC or between betaPV and basal cell carcinoma.

123 elioma, meningioma, renal cell carcinoma and basal cell carcinoma.

124 n the proliferation of colorectal cancer and basal cell carcinoma.

125 (HR = 1.15, 95% CI 1.11-1.19, p < 0.001, for basal cell carcinoma; HR = 1.21, 95% CI 1.17-1.25, p < 0

126 procaspase-8) in association with cutaneous basal-cell carcinoma (BCC) and linked to a germline SNP

127 ell carcinoma tumour burden and prevents new basal-cell carcinoma growth in patients with basal-cell

128 ular oedema in six (2%) versus six (1%), and basal-cell carcinoma in 14 (4%) versus nine (2%).

129 oma in ten (12%), asthenia in four (5%), and basal-cell carcinoma in four (5%).

130 The mean number of basal-cell carcinoma lesions at week 73 was reduced from

131 erruption of treatment, which is followed by basal-cell carcinoma recurrence.

132 on (aOR, 2.13; 95% CI, 1.31-3.47; P=.002) or basal-cell carcinoma specific criteria (aOR, 9.35; 95% C

133 the smoothened inhibitor vismodegib reduces basal-cell carcinoma tumour burden and prevents new basa

134 Vismodegib reduces basal-cell carcinoma tumour burden in patients with basa

135 is approved for use in adults with advanced basal-cell carcinoma.

136 confirmed, including 9 melanomas (0.5%), 37 basal cell carcinomas (1.9%), and 1 squamous cell carcin

137 way is aberrantly activated in a majority of basal cell carcinomas (BCC).

138 Basal cell carcinomas (BCCs) are diagnosed by clinical e

139 Advanced basal cell carcinomas (BCCs) frequently acquire resistan

140 The incidence of basal cell carcinomas (BCCs) is increasing globally, but

141 Human basal cell carcinomas (BCCs) very frequently carry p53 m

142 sting of squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs), are the most common human

143 ) have a greater risk of developing numerous basal cell carcinomas (BCCs).

144 ) have a greater risk of developing numerous basal cell carcinomas (BCCs).

145 Approximately 75% to 80% are basal cell carcinomas and 20% to 25% are squamous cell c

146 d specificity of 89-99% for the detection of basal cell carcinomas and can potentially serve as a rap

147 ed as nonmelanocytic (primarily as pigmented basal cell carcinomas and squamous cell carcinomas).

148 e reveals that dermoscopy can help delineate basal cell carcinomas before surgical removal but that i

149 which numerous indolent, well-differentiated basal cell carcinomas develop primarily on the face and

150 odalities to help delineate tumor margins of basal cell carcinomas in the setting of Mohs micrographi

151 lleagues and Sharpe and colleagues show that basal cell carcinomas resistant to the Smoothened (SMO)

152 eic keratosis, lichen planus-like keratosis, basal cell carcinomas) misclassified as melanocytic beca

153 n lesions (8 nevi, 8 seborrheic keratoses, 7 basal cell carcinomas, 7 melanomas, 4 hemangiomas, 4 der

154 luding 55 melanocytic nevi, 20 melanomas, 15 basal cell carcinomas, 7 solar lentigines or seborrheic

155 nderlie the development of infundibulocystic basal cell carcinomas.

156 as well as renal, breast, lung, gastric, and basal cell carcinomas.

157 ve for select locally advanced or metastatic basal cell carcinomas.

158 d cords, and ulceration were associated with basal cell carcinomas.

159 ltiple, recurrent, locally aggressive facial basal cell carcinomas.

160 UVR in sunlight causes mutations that drive basal cell carcinomas.

161 up and the placebo group with respect to new basal-cell carcinomas (20% [95% CI, -6 to 39] lower rate

162 on the incidence of new surgically eligible basal-cell carcinomas after 3 months of treatment.

163 y, had serious adverse events, including two basal-cell carcinomas and one major cardiovascular adver

164 e number of new squamous-cell carcinomas and basal-cell carcinomas and the number of actinic keratose

165 ndrome with at least ten surgically eligible basal-cell carcinomas at the Children's Hospital Oakland

166 baseline in the number of clinically evident basal-cell carcinomas at week 73.

167 mean reduced rate of new surgically eligible basal-cell carcinomas compared with patients randomly as

168 d the development of new surgically eligible basal-cell carcinomas compared with placebo (0.4 [SD 0.2

169 Fewer new surgically eligible basal-cell carcinomas developed in patients receiving vi

170 ing (mean 0.6 [0.72] new surgically eligible basal-cell carcinomas per patient per year vs 1.7 [1.8]

171 lacebo (0.4 [SD 0.2] new surgically eligible basal-cell carcinomas per patient per year vs 30.0 [7.8]

172 (n=15; two [SD 0.12] new surgically eligible basal-cell carcinomas per patient per year vs 34 [1.32]

173 r year vs 30.0 [7.8] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001).

174 er year vs 34 [1.32] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001).

175 er year vs 1.7 [1.8] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001).

176 umber of new nonmelanoma skin cancers (i.e., basal-cell carcinomas plus squamous-cell carcinomas) dur

177 Patients with multiple basal-cell carcinomas, including those with basal-cell n

178 al, we enrolled adult patients with multiple basal-cell carcinomas, including those with basal-cell n

179 ehog signalling underlies the development of basal-cell carcinomas.

180 onfirmed and at least six clinically evident basal-cell carcinomas.

181 ib dosing regimens in patients with multiple basal-cell carcinomas.

182 long-term regimens in patients with multiple basal-cell carcinomas.

183 roliferation, and leads to the expression of basal cell characteristics, including stem cell potentia

184 he invaginated plasma membrane retracts when basal cell closure normally begins.

185 bilize the forming basal membrane and enable basal cell closure.

186 stem cells (LSCs) are affected globally and basal cell density could be used as a parameter to measu

187 There was a trend of basal cell density decline in more advanced stages of LS

188 The basal cell density declined in the unaffected regions at

189 Basal cell density in all locations was measured by 2 in

190 Basal cell density in both central cornea and limbus dec

191 In the LSCD group, the mean basal cell density in the cornea decreased 31.0% (6389 +

192 The mean basal cell density of the normal group was 9264 +/- 598

193 The basal cell diameter increased by 24.6% in the cornea (14

194 CRISPR/Cas9 genome editing in primary human basal cells differentiating into organoids and mucocilia

195 ells still gave rise to basal cells, whereas basal cells divided only into basal cells.

196 in in vivo leads to misorientation of apical-basal cell division in nephron tubules.

197 ORs are first expressed around 4 d following basal cell division, 24 h after OSN axons have reached t

198 e molecular development of OSNs beginning at basal cell division, including the onset of OR expressio

199 N maturation and axon extension beginning at basal cell division.

200 that beta-catenin signaling is activated in basal cells during early pregnancy, and demonstrate that

201 cells and tested their potential to produce basal cells during tumorigenesis.

202 cally constricting cells to undergo aberrant basal cell extrusion and cell intercalation.

203 tion period of 6 hours, but we observed that basal cells flattened to cover the basement membrane.

204 oscopy and by examining isolated luminal and basal cell fractions.

205 In the airway epithelium, basal cells function as stem/progenitor cells that can b

206 Consistent with this profile, basal cells functionally exhibit intrinsic stem-like and

207 Cs) and some among the population of globose basal cells (GBCs) are stem cells, but the two types pla

208 Of clinical relevance, the basal cell gene-expression profile is enriched in advanc

209 milar cells develop that express a subset of basal cell genes, including keratin 5, but no longer exp

210 Horizontal basal cells (HBCs) act as reserve stem cells and remain

211 Both horizontal basal cells (HBCs) and some among the population of glob

212 pairs proliferation of progenitor horizontal basal cells (HBCs) and subsequent neuronal differentiati

213 pulation of basal stem cells, the horizontal basal cells (HBCs), in the olfactory epithelium (OE).

214 of two stem cell populations: the horizontal basal cells (HBCs), which are quiescent and held in rese

215 ssion is activated in a subset of horizontal basal cells (HBCs), which repopulate all microvillar cel

216 globose basal cells and quiescent horizontal basal cells (HBCs).

217 identify Notch signaling as a determinant of basal cell heterogeneity and fate decisions in pseudostr

218 on of epithelial eosinophilia in addition to basal cell hyperplasia and vascular remodeling.

219 s mediated by BMP-driven NRF2 activation and basal cell hyperplasia is promoted by disruption of BMP

220 , little is known about the specific role of basal cells in antimicrobial protein and peptide product

221 e ALT pathway is expressed in stem cells and basal cells in epidermal SCC in Terc(-/-) mice, and in s

222 Telomeres shorten markedly in stem cells and basal cells in epidermal SCC in vivo.

223 Basal cells in pseudostratified epithelia display a sing

224 We show that basal cells in the epidermis maintain telomeres both by

225 vealed enrichment of cytokeratin 14-positive basal cells in the hyperplastic urothelial mucosa in mal

226 ovide evidence that the p63(+)KRT5(+)KRT7(+) basal cells in this zone are the cells of origin for mul

227 that stimulated differentiation of prostatic basal cells into transformation-preferable luminal cells

228 ing, a known negative regulator of embryonic basal cells, is also necessary for maintenance of the pr

229 uency of marked atypia on melanocytes in the basal cell layer; it presented with lower ABCD Total Der

230 neages that form the inner luminal and outer basal cell layers, with stem and progenitor cells contri

231 these findings show that Ezh2 restricts the basal cell lineage during normal lung endoderm developme

232 Here we show that AR is dispensable for basal cell maintenance, but is cell-autonomously require

233 lls, reduced proportions of SAE ciliated and basal cells, markedly abnormal SAE and alveolar macropha

234 nal characteristics, such as p63(+) cells (a basal-cell marker) showing luminal-like morphology, or c

235 on of membrane pores through both apical and basal cell membrane layers that reseal along their later

236 ither bulk or FACS-sorted single luminal and basal cells), metastatic prostate cancer lesions and cir

237 ndependent datasets derived from luminal and basal cell models provides evidence that PCS1 and PCS2 t

238 ost BCCs are sporadic, rare individuals with basal cell nevus syndrome (BCNS) harbor germline defects

239 Patients with basal cell nevus syndrome (BCNS) have a greater risk of

240 Importance: Patients with basal cell nevus syndrome (BCNS) have a greater risk of

241 d or metastatic orbital or periocular BCC or basal cell nevus syndrome and can obviate orbital exente

242 After exclusion of patients with basal cell nevus syndrome and immunocompromise, 1284 pat

243 nical follow-up time, immunosuppression, and basal cell nevus syndrome status.

244 .89-16.97; P < .001), accounting for age and basal cell nevus syndrome status.

245 d or metastatic orbital or periocular BCC or basal cell nevus syndrome treated with the Hedgehog path

246 ls, without other features characteristic of basal cell nevus syndrome.

247 Ten patients had locally advanced BCC; 2 had basal cell nevus syndrome.

248 ntrolled, phase 2 trial in patients with the basal-cell nevus (Gorlin) syndrome indicating that the s

249 basal-cell carcinomas, including those with basal-cell nevus (Gorlin) syndrome, need extended treatm

250 l we enrolled patients aged 35-75 years with basal-cell nevus syndrome with at least ten surgically e

251 nt assignment was stratified by diagnosis of basal-cell nevus syndrome, geographical region, and immu

252 basal-cell carcinomas, including those with basal-cell nevus syndrome, who had one or more histopath

253 ell carcinoma tumour burden in patients with basal-cell nevus syndrome.

254 basal-cell carcinoma growth in patients with basal-cell nevus syndrome.

255 rks a subset of BLBC with a putative mammary basal cell of origin.

256 polarity remodeling occurs in proliferative basal cells of mammalian epidermis whereupon cell divisi

257 we found that deletion of Fgfr1 or Spry2 in basal cells of the adult mouse trachea caused an increas

258 Rpn6 is overexpressed in myofibroblasts and basal cells of the bronchiolar epithelium in lungs of pa

259 t primary cilia are predominantly present on basal cells of the mouse corneal epithelium (CE) through

260 3a mRNA and GFP are expressed within globose basal cells of the olfactory and vomeronasal epithelium

261 tenance of HPV infection in undifferentiated basal cells of the squamous epithelia requires the activ

262 Basal cells of WTs and epidermoid cells of MECs were str

263 that luminal cells are capable of producing basal cells on activation of either polyoma middle T ant

264 umor results from transformation of bipotent basal cells or from transformation and subsequent basal

265 re also described that promote enrichment of basal cells organized into multiple layers surrounding a

266 Basal cells play a critical role in the response of the

267 the establishment and maintenance of apical-basal cell polarity.

268 d that the Krt15 promoter marks a long-lived basal cell population able to self-renew, proliferate, a

269 is highly expressed in MaSC-enriched mammary basal cell population and in mammary tumors, and is regu

270 disrupting Notch ligand activity within the basal cell population at large disrupts the normal patte

271 concomitant gain of the CD24(mid)/CD49f(hi) basal cell population at maturity.

272 One basal cell population displays intracellular Notch2 acti

273 of ZEB1 and CD117 are found in the prostate basal cell population of DAB2IP knockout mice.

274 to show that this squamous-columnar junction basal cell population serves as a source of progenitors

275 s a stem cell-enriched subset of the mammary basal cell population.

276 tes that most ckPCs reside among the globose basal cell populations and act downstream of horizontal

277 onal expansion of single human cells and for basal cell populations from epithelial tissues from all

278 ables robust expansion of primary epithelial basal cell populations.

279 Strikingly, basal cells preferentially express gene categories assoc

280 ort here the surprising discovery that these basal cell projections--which we call axiopodia--periodi

281 other receptor tyrosine kinases and restrain basal cell proliferation.

282 Basal cells provide structural and contractile support,

283 However, how basal cells respond to the inflammatory environment at t

284 FGF receptor 2 (FGFR2) in adult mouse airway basal cells results in self-renewal and differentiation

285 ful cultures were prepared using adult mouse basal cells selected for expression of c-KIT.

286 expression of a key transcription factor for basal cell self-renewal and differentiation: SOX2.

287 We show that in airway basal cells, SPRY2 is post-translationally modified in r

288 the oestrogen receptor-expressing, milk and basal cell subpopulations have telomere lengths and cell

289 uamous epithelium comprised of proliferative basal cells that differentiate while migrating toward th

290 lly coupled to the basal layer by peripheral basal cells that extend apically and centripetally while

291 e ectopic and premature appearance of Trp63+ basal cells that extend the entire length of the airway.

292 a gene signature specific for human prostate basal cells that is differentially enriched in various p

293 The GBC population includes the basal cells that proliferate in the uninjured OE and is

294 cate the long axis orientation of interphase basal cells to neighbouring basal mitoses so that they a

295 erged cultured PBEC (primarily consisting of basal cells) to the respiratory pathogen nontypeable Hae

296 erial contain the differentiated luminal and basal cell types, whereas organoids derived from prostat

297 Human airway basal cells were differentiated and cultured at air-liqu

298 ow but intermediate cells still gave rise to basal cells, whereas basal cells divided only into basal

299 populations and act downstream of horizontal basal cells, which can serve as stem cells.

300 innate immune activity of airway epithelial basal cells, which serves as a second line of airway epi